We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
from Part 3.4 - Molecular pathology: endocrine cancers
Published online by Cambridge University Press: 05 February 2015
Introduction
Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominantly inherited disorder characterized by medullary thyroid carcinoma (MTC), pheochromocytoma (PC), and primary parathyroid hyperplasia (PPH). While the penetrance of MTC is nearly 100%, there is much inter- and intra-family variability in the other clinical manifestations of this disorder. An MEN2 syndrome is often first suspected when a patient is found to have one or more of these tumors and especially at a young age. MEN2 is subclassified into three distinct syndromes: MEN2A, MEN2B, and familial medullary thyroid carcinoma (FMTC). Although these syndromes are rare, early identification enables adequate treatment and evaluation of family members. Because the predisposing gene is known (the RET proto-oncogene), molecular testing by DNA mutation analysis is now available for detecting pre-symptomatic patients with MEN2. Early detection and treatment improves life expectancy and quality of life.
Medullary thyroid carcinoma (MTC)
MTC is a neuroendocrine tumor of the parafollicular or C-cells of the thyroid gland, accounting for approximately 3 to 5% of all thyroid carcinomas. C-cells are neuroendocrine cells derived from the ultimobranchial bodies (transient embryonic structures), which fuse with the posterior lobes of the thyroid; C-cells make up only about 0.1% of the thyroid mass. Multi-centric hyperplasia of the parafollicular C-cells is the hallmark of MEN2, with a penetrance approaching 100%. C-cell hyperplasia (CCH) clearly is a precursor lesion of MTC (see Figure 66.1). Nearly all MEN2 patients develop clinically apparent MTC, often early in life (1). A characteristic feature of thyroid C-cells and MTC is the production of the blood calcium-lowering peptide hormone calcitonin (2–4). The diagnoses of CCH and MTC are based upon microscopy criteria (histopathology, see Figure 66.1; 5). Neoplastic CCH and MTC in MEN2 are caused by a germline mutation in the RET proto-oncogene; MTCs in MEN2 patients are multi-centric and concentrated in the upper third of the thyroid gland (see Figure 66.2), reflecting the normal distribution of parafollicular thyroid C-cells.
To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Find out more about the Kindle Personal Document Service.
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.
